Company Overview

WE INVITE CONSTRUCTIVE DISRUPTION.

…to challenge the status quo.

…to push the benchmarks of success.

Because we see a way to a better future and a better self through reshaping vision possibilities.

Orasis is an emerging ophthalmic pharmaceutical company with an FDA approved prescription eye drop, QLOSI™, for presbyopia as an alternative to reading glasses. Presbyopia is the gradual loss of your eye’s ability to focus on near objects, which begins to affect most people sometime after the age of 40 and affects more than 1.8 billion people worldwide.

Orasis is led by a collaborative team of industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development

Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors including the ophthalmology focused venture capital fund Visionary Ventures, Bluestem Capital, Sequoia Capital, SBI (Japan) Innovation Fund, LifeSci Venture Partners, Maverick Ventures Israel, and other private investors.

Orasis has offices in the US and Israel.